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ABSTRACT 
The Impact of Mechanical Properties of Poly(ethylene Glycol) 
Hydrogels on Vocal Fold Fibroblasts’ Behavior. (May 2007) 
Huimin Liao, B.S., Fudan University;  
M.S., National University of Singapore  
Chair of Advisory Committee: Dr. Mariah Hahn 
 
Vocal fold scarring, caused by injury and inflammation, presents significant treatment 
challenges.  Tissue engineering might be a promising treatment for vocal fold 
restoration or regeneration.  It is important to investigate how scaffold properties 
alter cell behavior instead of screening thousand of materials, which is fundamental 
knowledge for rational scaffold design.  This work studies how tuning only one 
parameter, mechanical strength of the hydrogel scaffold, influences the extracellular 
matrix production of encapsulated porcine vocal fold fibroblast (PVFF).  PVFF cells 
were encapsulated by photopolymerization in 10 wt%, 20 wt%, and 30 wt% 
poly(ethylene glycol) diacrylate (PEGDA) hydrogels (MW 10,000), with the similar 
biochemical environment and network structure but different mechanical properties.  
Cell adhesive peptide, RGDS, was grafted into each hydrogel network to mimic a cell 
adhesive environment.  The glycosaminoglycans (GAGs) production per cell 
increased from 10 wt% to 20 wt%, 30 wt% gels, with an increase in hydrogel 
stiffness.  The collagen production per cell increased from 10 wt% to 20 wt% gels 
but no further increase occurred with the increasing modulus from 20 wt% to 30 wt% 
gels.  Interestingly, in hydrogels of intermediate modulus (20% PEGDA hydrogels), 
the highest elastin per cell was observed compared with gels with higher and lower 
storage modulus after day 30.  Histological analysis showed GAGs, collagen and 
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elastin were distributed pericellularly.  However, the organization of collagen type I 
appeared to be influenced by gel mechanical properties, which was confirmed by 
immunohistological analysis.  Furthermore, the immunohistological analysis 
showed that the phenotype of PVFF is regulated by the stiffness of the PEG hydrogel.  
This study demonstrates that different levels of VFF ECM formation may be 
achieved by varying the mechanical properties of PEG hydrogels and validates a 
systematic and controlled platform for further research of cell-biomaterials 
interaction. 
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1. INTRODUCTION FOR VOCAL FOLD SCARRING AND RESTORATION 
1.1. The Anatomy of Vocal Fold 
Voice quality is dependent on the unique layered ultrastructure of the vocal fold [1].  
Histologically, the human vocal fold is composed of three distinct layers (Figure 1): 1) 
the “cover”, which includes the outer epithelia and superficial lamina propria (SLP); 2) 
the vocal “ligament”, including intermediate lamina propria (ILP) and deep lamina 
propria (DLP); and 3) the body, composed of thyroarytenoid muscle [1, 2].  The SLP is 
composed of interstitial proteins, such as fibronectin, and a relatively low density of 
collagen and elastin fibers.  On the other hand, the intermediate lamina propria and 
deep lamina propria are composed of well-oriented of collagen and elastin fibers, with a 
relatively low density of interstitial proteins [3, 4].  The lamina propria has been 
described as viscoelastic [2, 4, 5], and the elastic and viscous shear properties of 
lamina propria must be in appropriate balance for normal vocal fold vibration [2].  
 
Generally, scarring changes the viscoelastic structure of the lamina propria, causing an 
increase in stiffness so that the normal mucosal wave is disrupted during phonation. 
This results in hoarseness or raspy voice, increased vocal effort, voice breaks, vocal 
fatigue, and possibly breathy voice quality [2 - 5].  Study has shown that vocal fold 
scarring is most frequently limited to the SLP [2].  Developing a tissue-engineered 
construct that mimics SLP behavior is therefore important to the vocal fold scar 
restoration. 
This thesis follows the style of Journal of the American Chemical Society. 
 2 
 
Figure 1. The structure of human vocal fold. [1] 
 
1.2. Vocal Fold Scarring 
In the world, it is estimated that from 3% to 9% of population suffer from vocal fold 
disorders across the lifespan [6].  Vocal fold scarring, whose formation is induced in 
response to injury or inflammation, is the greatest cause of poor voice and presents 
significant treatment challenges [6 - 9].  Figures 2 (a) and (b) compare the vibratory 
cycles in normal and scarred vocal folds respectively.  In voice production, air is 
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forced out from the lungs.  This fast-moving air stream produces a Bernoulli Effect 
as it encounters the vocal fold: the induced low pressure causes the bottom of the 
vocal fold to close, followed by the top.  This closure of the vocal fold cuts off the 
air flow and releases a pulse of air, completing a vibratory cycle.  Scarring hampers 
the vibratory cycle, resulting in incomplete closure of the vocal folds (known as 
glottal insufficiency) and hence poor voice (panel 2 and panel 8 in Figure 2 (b)) [1-2, 
7].  
  
 
   (a)           (b) 
Figure 2. (a)Vibration of normal vocal fold tissue. (b) Vibration of scarring vocal fold 
tissue. ◆ represents scarring tissue. [1]  
 
 
Research has shown that scarring increases the stiffness of the lamina propria, in 
particular that of the SLP, so that the normal mucosal wave is disrupted during 
phonation, which results in hoarseness or raspy voice, increased vocal effort, voice 
breaks, vocal fatigue, and possibly breathy voice quality [6 - 9]. 
1.3. Extracellular Matrix Composition of Normal and Scarred Lamina Propria 
The extracellular matrix (ECM) does not only provide structure and support for tissue, 
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but also promotes cell adhesion, migration, growth, differentiation and activates 
intracellular signaling [2, 10].  The ECM of the lamina propria includes fibrillar 
proteins, such as collagen and elastin, interstitial proteins such as fibronectin, and 
proteoglycans and glycosaminoglycans (Figure 3).  Fibroblasts, the primary cell type 
composing the lamina propria, contribute to the deposition, degradation and 
rearrangement of ECM [11].  Collagen is one of the most important tissue structural 
proteins and is critical to bearing stress and resisting deformation during phonation [2, 
12].  Collagen Type I is the most ubiquitous fibrillar collagen in both the skin and the 
vocal folds, providing a structure of high tensile strength [13].  Elastin, which is sparse 
in the SLP [7, 9], is made of highly hydrophobic crosslinked proteins and enables the 
tissue to return to its original shape after deformation [2].  Fibronectin, an ECM 
glycoprotein, is an important adhesion molecular, which contributes to matrix 
organization and wound healing. Another important ECM component is 
glycosaminoglycans (GAGs), unbranched polysaccharide chains composed of 
repeating disaccharide units.  Since GAGs are negatively charged and strongly 
hydrophilic, they allow the tissue to absorb large amount of water and to withstand 
large compressive forces [2].  
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Figure 3. Schematic of ECM in SLP of lamina propria of younger adult. [14] 
 
Studies in animal models have shown that the density and organization of the ECM 
components determine the biomechanical properties and vibratory behavior of the 
lamina propria and that the ECM distribution and density are changed in both acute 
and chronic vocal fold scarring (Table 1) [6 - 9].  In scarred vocal folds, collagen 
lacks its characteristic organization into parallel bundles [8, 10, 15].  In addition, it 
appears that elastin is frequently less dense and more disorganized in scarred vocal 
folds [16].  A decrease in GAG and water in the ECM in scarred vocal folds has been 
observed [2].  The development of treatment for vocal fold scarring must be based on 
the comprehensive understanding regarding the roles of ECM proteins in vocal fold 
vibratory function.   
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Table 1. Summary of Histologic Changes in ECM Components in Scarred Vocal Folds 
of Different Animal Models. [8] 
 
ECM component 3d 5d 10d 15d 2 mo 6 mo 2 mo 6 mo 3d 10d 15d 2wk 1 mo 2 mo 3 mo
Procollagen ↑ ↑
Collagen ↓ ↑ ↑ ↑ ↑ ↑ ↑ ↑
Elastin ↓ ↓ ↓
Fibronectin ↑ ↑ ↑ ↑ ↑
Hyaluronan ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
↑= increase; ↓=decrease;  = no change; blank = not measured
Injured Rabbit
 Vocal Fold
Injured Canine
Vocal Fold
Injured Pig
Vocal Fold
Injured Rat
Vocal Fold
 
1.4. Phenotype of Fibroblasts in Lamina Propria 
Fibroblasts are the primary cell type in normal lamina propria, expressing vimentin [2, 
13, 17, 18].  Fibroblasts in scarred lamina propria change their phenotype into 
myofibroblasts, which have characteristic of both smooth muscle cells and fibroblasts 
[13].  Myofibroblasts show increased production of matrix proteins, functioning to 
repair injuries in the lamina propria [2].  Studies have demonstrated environmental 
cues tend to stimulate fibroblast differentiation into proto-myofibroblasts, an 
intermediary cell type between fibroblasts and true myofibroblasts, expressing smooth 
muscle α-actin (SMα-actin) and vimentin at the same time [18].  The 
proto-myfibroblasts differentiate into myofibroblasts by the stimuli of growth factors, 
newly synthesized ECM proteins and mechanical loading.   
1.5. Current Treatment for Vocal Fold Scarring 
The goals of treatments for lamina propria scarring are to: 1) restore normal lamina 
propria pliability and geometry; 2) reduce the force associated with voice production 
and vocal fatigue; 3) improve overall voice quality [1].  To soften or replace scarred 
tissue, some medical treatments are being developed for vocal fold scarring.  However, 
current clinical treatments produce inconsistent and suboptimal results, which makes 
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vocal fold scarring a major problem awaiting improvement in the future [8]. 
 
Speech therapy is an important preliminary step in treatment of patients with vocal 
fold scarring [8, 9].  Speech therapy trains patients to use appropriate voice behavior 
and assists the patients in compensating for the voice problems.  A limitation of 
speech therapy is that it does not directly change the histological nature of the scarred 
vocal folds so that it cannot restore function to scarred tissue, only improving the 
manner in which it is used. 
 
Surgical treatments are performed to improve glottal insufficiency during voice 
production [8, 9].  This approach enables the better vocal fold closure and better 
vocal fold vibration.  However, the scarred tissue remains in the lamina propria and 
the normal vibratory properties of the vocal folds cannot be restored. 
 
Biomaterial injection into the SLP is the most popular clinical treatment currently.  
Bovine collagen, autologous collagen, autologous fat and hyaluronan (HA) have been 
injected into scarring tissue [8, 9, 19 - 24], with the aim of augmenting the lamina 
propria and softening the scarred tissue (Table 2).  However, the success of such 
implants to achieve normal viscoelastic properties of vocal folds has been limited.  
In addition, resorption of injectable materials over time is another issue which results 
in implant failure. 
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Table 2.  Summary of Studies on Biomaterial Injection [7] 
Type of 
treatment Reference Outcome 
Homologous 
collagen matrix 
injected in 
scarred vocal 
folds 
in rabbits 
Kriesel K et al. 
*Homologous collagen matrix simulated 
production of high quality procollagen 
*Homologous collagen matrix did not 
improve the biomechanical properties of 
scarred vocal fold 
Collagen 
treatment of 
scarred vocal 
fold: case studies 
Bjorck G et al. 
*All patient had improved voice vibration 
after treatment 
*3 out of 4 patients had increased amplitude 
of vibration 
*2 out of 4 patients' voice quality had been 
improved 
*None of patients had experienced any side 
effect. 
Autologous fat 
implantation  
for vocal fold 
scar 
Neuenschwander 
MC et al. 
* Patients had shown improvement on vocal 
fold function and quality of voice  after 
injection with autologous fat 
Autologous fat 
implantation into 
the vibratory 
margin for 
vocal fold scar 
Hsiung MW et al. 
* 7 out of 13 patients had improved in vocal 
fold function, 2 of them showed failure after 
2 and 3 months, 2 were lost to follow-up and 
2 showed no change.   
Hyaluronic 
acid(HA) 
injection in 
rabbit model: 
Short-time study 
Hertegard S 
et al. 
* HA might alter viscoelasticity scarred 
vocal folds after 8 weeks 
*There was large variation in stiffness 
between two types of hyaluronan  
Cross-linked 
hyaluronan for 
treatment of 
glottal 
insufficiency 
Hertegard S 
et al. 
* The patients showed better vocal fold 
status and vocal function after 12 months 
treatment. 
* Less resorption of hylan B gel was 
observed at the injected vocal fold edge 
* 3 patients showed temporary 
inflammation, which resolved without 
sequelae. 
 
Growth factor therapy might be a potential treatment for vocal fold scarring by 
modifying fibroblast activity and reconstructing ECM of the vocal fold to improve 
vibration.  Hirano S et al. applied hepatocyte growth factor (HGF) to the scarred 
vocal folds in a canine model since HGF has strong anti-fibrotic activity [25].  After 
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6 month treatment with HGF, less deposition of collagen, a decrease in elastin, less 
contraction of lamina propria and better mucosal wave amplitude were observed in 
treated vocal folds compared with untreated scarred vocal folds.  However, vocal 
function was still reduced in the treated group as compared with the normal group.   
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2. TISSUE ENGINEERING 
2.1. Tissue Engineering Approach 
Tissue engineering has been demonstrated to be a powerful general strategy for tissue 
regeneration [26, 27, 28] and has great potential to restore function to scarred lamina 
propria [7].  Three important elements are manipulated in tissue engineering: (1) 
scaffolds, (2) cells and (3) regulatory factors (Figure 4).  The most common strategy in 
tissue engineering is to use a scaffold to support, guide and simulate living cells to 
regenerate tissues.  Changes in scaffold features, like network structure, mechanical 
properties or biochemical properties, can cause different cell responses [27, 29].  Vocal 
fold scarring might be eventually cured by using scaffolds, cells and regulatory factors 
together appropriately [9]. 
 
 
 
 
Figure 4. Tissue engineering approaches. Tissue engineering approaches are classified 
into three categories: (i) cells alone, (ii) cells with scaffolds, and (iii) scaffolds alone. 
Each one of these approaches can be enhanced by in vitro microenvironmental factors 
before application as a tissue substitute. [24] 
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Researchers have attempted to engineer tissue substitutes for skin, cartilage, bone, 
blood vessels, nerve, cornea, liver and kidney [26, 27].  Skin may be the most 
successful tissue engineered substance, and there are several FDA approved products in 
the market (i.e. TransCyte from Advanced Tissue Sciences, Apligraf from 
Organogenesis) [28].  In addition, tissue engineering of bone and cartilage has also 
experienced relative success [26 - 28].  Tissue engineering approach might have great 
potential to restore vocal function and generate the vocal folds. 
 
Hahn MS et al. investigated collagen-alginate hydrogels seeded with fibroblast in vitro 
as a potential biomaterial for vocal fold restoration [30].  Collagen-alginate hydrogels 
resisted scaffold compaction and maintained their original shape and mass through 42 
days in culture while allowing cells to synthesize new ECM.  Kanemaru S et al. 
reported the use of mesenchymal stem cells (MSC) to treat vocal fold scarring [31].  
MSCs were incubated in 1% hydrochloric acid atelocollagen then injected into injured 
vocal folds in a canine model.  It was found 3-dimensional incubated MSCs promoted 
wound healing in terms of vocal fold appearance and histology.  However, it is unclear 
how implanted cells acted in the vocal folds and controlled methods to induce 
appropriate stem cell differentiation are critical to obtain ideal results. 
2.2. Challenges in Current Scaffold Engineering 
Despite significant success in skin and cartilage tissue engineering, there are a number 
of challenges remaining in “off-the-shelf” tissue production.  For example, available 
tissue engineered skin products only act as passive wound covers, lacking essential 
function and components of native skin [28].  Today, although researchers have 
gained more and more new knowledge, there are deficits in fundamental 
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understanding in tissue engineering.  For instance, those related to structural and 
mechanical aspects of tissues, the behavior of biomaterials, and the cell-material 
interactions [26 - 28].  Furthermore, there is little progress toward a systematization 
of tissue engineering through the development of a foundation of broadly applicable 
theoretical principles relating cell behavior to scaffold material properties.  However, 
such a foundation is needed for rational scaffold design [29].    
 
As a consequence, there is a great demand to understand the complex interactions 
between scaffold features and cell responses so that cell response can be optimized by 
rationally tuning the scaffold material.  However, scaffold features are usually 
interdependent, and this makes it difficult to investigate the dependence of cell response 
on isolated scaffold properties.  For example, the mesh size of hydrogel network is 
interdependent with mechanical properties so that the cell response to the hydrogel 
results from both parameters [32 - 34].   It is necessary to create a 3-D platform in 
which the impact of isolated material properties on cell behavior can be systematically 
explored. 
2.3. Proposed 3D Platform 
Poly(ethylene glycol) (PEG) hydrogels have been chosen to fabricate the platform.  
The advantages of PEG-based hydrogels in tissue engineering are many: 1) PEG 
hydrogels are biocompatible.  Thus the cells could be encapsulated in hydrogels 
without compromising their viability [35 - 38]; 2) The semi-permeability of PEG 
hydrogels allows nutrients, wastes, dissolved gases and water-soluble metabolites to 
pass through the gels while inhibiting the infiltration of  the components of the 
immune system, thereby preventing the rejection of transplanted cells by the host’s 
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immune system [39, 40]; 3) The water content and mechanical properties of PEG 
hydrogels can be tailored to be similar with some soft tissue (i.e. cartilage) by adjusting 
the concentration and molecular weight of PEG macromers [33, 35, 41]; 4) PEG 
hydrogels are essentially non-biodegradable.  However, it is easy to modify PEG 
macromer backbone to create PEG derivatives with predictable and controllable 
degradation times  [33, 35, 37, 42]; 5) Due to hydrophility and steric hindrances 
caused by mobile PEG chains, PEG hydrogels are intrinsically resistant to protein 
adsorption and cell adhesion, creating a biological blank “slate” into which desired 
bioactivity can be incorporated [43, 44].  Thus, the biochemical stimuli experienced 
by the cell can be tightly controlled.  And 6) the mesh size and mechanical properties 
of PEG hydrogels can be tuned in an uncoupled manner.   
 
This work will use PEGDA hydrogels to study the effect of isolated mechanical 
properties on vocal fold fibroblast’s cellular ECM production.  Since fibronectin is an 
important lamina propria interstitial protein and has significant functions in wound 
healing and cell adhesion, cell adhesion peptide Arg-Gly-Asp (RGD) [2], will be 
immobilized into poly(ethylene glycol) hydrogels in the present work to create 
materials that mimic some biochemical properties of the native ECM [38].  Although 
significant research has been conducted on the effects of the hydrogel properties on cell 
response [32, 33, 34, 38], the effects of isolated material properties (e.g., mechanical 
properties alterations independent of biochemical or microstructural changes) on cell 
behavior have not been explored.   The broad thematic purpose of this research is to 
create a systematic and controlled approach to identify optimal scaffold parameters for 
scarred vocal fold restoration and regeneration.  Our work should make significant 
contributions to help tissue engineering become a viable method for vocal fold scarring 
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treatment. 
 15 
3. MATERIALS AND METHODS 
The purpose of the current study was to elucidate the relationship between 
biomechanical properties of PEG hydrogel scaffold and ECM synthesis of porcine 
vocal fold fibroblasts (PVFF) when encapsulated in PEG hydrogels with immobilized 
RGDS peptides.  PVFF were photoencapsulated in PEGDA (MW 10,000 Da) 
hydrogels of similar mesh sizes but varying biomechanical properties.  The 
biochemical composition and distribution of ECM in cell-hydrogel constructs was 
examined as a function of the gel mechanical properties. 
3.1. Synthesis of PEGDA  
PEG diacrylate was synthesized by mixing 0.1 mmol/ml dry PEG (MW 10,000 Da, 
Fluka, Milwaukee, WI), 0.4 mmol/ml acryloyl chloride (ACRŌS, Geel, Belgium) and 
0.2 mmol/ml triethylamine (J.T. Baker, Phillipsburg, NJ) in anhydrous 
dichloromethane (DCM) and stirring in argon environment overnight.  The resultant 
solution was washed with 2 M K2CO3 solution and separated into two phases: 
aqueous and organic DCM phases.  The DCM phase was collected and dried by 
anhydrous MgSO4 (Fisher Scientific, Fair Lawn, NJ).  Subsequently PEGDA was 
precipitated in diethyl ether (Fisher Scientific, Fair Lawn, NJ), filtered, and dried 
under vacuum at room temperature.  
3.2. Acrylation of RGDS 
The peptide RGDS (American Peptide, Sunnyvale, CA) was reacted with 
acryloyl-PEG-N-hydroxysuccinimide (ACRL-PEG-NHS, MW 3400 Da; Nektar, 
Huntsville, AL) in 50 mM sodium bicarbonate buffer (pH = 8.5) at 1:1 molar ratio for at 
least 2 h.  The synthesized ACRL-PEG-RGDS was purified by dialysis, lyophilized 
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and stored at -80˚C until use.   
3.3. Mesh Size Determination 
3.3.1. Hydrogel Polymerization  
PEGDA was dissolved in HEPES-buffered saline (HBS; 10 mM HEPES, 150 mM 
NaCl, pH = 7.4,) at concentrations of 10%, 20%, and 30% (w/v).  10 μl/ml of 300 
mg/ml solution of 2,2-dimethyl-2-phenyl-acephenone (DMAP; TCI, Portland, OR) in 
N-vinylpyrrolidone (NVP; Sigma. St. Louis, MO) was added.  150 μl of each 
precursor solution was added to 48-well plates (Nalge Nunc, Rochester, NY), then 
photopolymerized for 2 min using a 365 nm transilluminator (Spectroline, Westbury, 
NY)  at intensity of ~ 9 mW/cm2 for 2 min.   
3.3.2. Swelling Studies and Hydrogel Characterization 
PEGDA hydrogel discs were blot dried and weighed immediately after polymerization 
and then allowed to swell in PBS (Hyclone, Logan, UT) at room temperature for 24 h 
to reach equilibrium.  The discs were then weighed again to determine the 
equilibrium swollen mass, sM .  The salt was removed from swollen hydrogel discs 
by soaking them in diH2O at room temperature for another 24 h.  The hydrogel discs 
were dried by lyophilization for at least 24 h to get the dry mass, dM .  A sample 
size of two was used.  The equilibrium water content ( q ) was calculated using the 
following equations: 
%1001 ´÷÷
ø
ö
çç
è
æ
-=
d
s
M
Mq               (1) 
 
The number average molecular weight between crosslinks, cM  can be determined 
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using the following equation [33]: 
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where v  = 0.870 cm3/g, the specific volume of bulk PEG in the amorphous state, 1V  
=18 cm3/mol, the molar volume of water, sv ,2  and rv ,2  are the polymer volume 
faction of the hydrogel in the relaxed and swollen state, respectively, c  = 0.426, the 
Flory-Huggins polymer-solvent interaction parameter, nM  = 10,000 Da, the number 
average molecular weight of PEGDA macromolecule.  The average mesh size, z , 
of the hydrogels network was estimated using the following equation [33, 42, 43]: 
2/1
2/1
3/1
,2
3
n
r
c
s CM
Mlv ÷÷
ø
ö
çç
è
æ
= -z                (3) 
Where l  = 1.50 Å, the backbone bond length, which was calculated by the weighted 
average of one-carbon-carbon bond and two carbon-oxygen bonds, rM  = 44 g/mol, 
the molecular weight of the PEG repeat unit, nC  = 4.0, the characteristic ration. 
3.4. Cell Maintenance 
Porcine vocal fold fibroblast cells (PVFF) were subcultured at 37˚C/5% CO2 in 
Dulbecco’s modified Eagle minimum essential medium (DMEM; Hyclone, Logan, 
UT) supplemented with 10% fetal bovine serum, 1 μg/ml bFGF, 50 mU/ml penicillin, 
50 μg/ml streptomycin and 2 mM L-glutamine [30].  The experiments were 
conducted using cells at passages 6-8. 
3.5. Cell Encapsulation 
Precursor solution at concentrations of 10%, 20% and 30% (w/v) containing 2 mM of 
ACRL-PEG-RGDS (moles/swollen volume of hydrogels) and 10 μl/ml of a 300 
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mg/ml DMAP/NVP photoinitiator solution were sterilized by filtration (0.22 μm, PES 
membrane, Millipore, Bedford, MA).  PVFF cells were trypsinized and resuspended 
in each precursor solution at a concentration of ~ 400,000 cells/ml (# cells/swollen 
volume of hydrogels).  2 ml of cell suspension was rapidly pipetted between two 
sterile clamped glass plates separated by 1.5 mm spacers and exposed to UV light 
(365 nm, ~ 9 mW/cm2) for 2 min under constant turnover of the gel constructs.  It 
has been shown that the longwave UV light used at similar intensities and exposure 
times for uniform photopolymerization results in minimal cell damage [44]. The 
prepared hydrogel constructs were transferred to a culture plate and incubated at 37˚C 
in a humidified environment with 5% CO2.  The hydrogel constructs were kept from 
the gas-media interface and the bottom surface of the plate by polyethylene spacers.   
The cell-encapsulated hydrogel constructs were cultured for 70 days in Dulbecco’s 
modified Eagle minimum essential medium (DMEM, Hyclone, Logan, UT) 
supplemented with 10% fetal bovine serum, 50 mU/ml penicillin, 50 μg/ml 
streptomycin and 2 mM L-glutamine.  The medium was replaced every other day.   
3.6. Compression Tests 
The cell/hydrogel constructs were cultured for 2 days before compression test to ensure 
saturating hydration and cut into round discs of 11.5 mm in diameter.  A sample size of 
3 was used.  The storage and loss moduli of each hydrogel disc were measured in 
compression mode using a dynamic mechanical analyzer (DMAQ800, TA Instruments, 
New Castle, DE).  The bottom plate was clamped rigidly while the top plate was 
connected to a motor that enabled oscillation of the plate.  Silicone oil (Fluka, 
Milwaukee, WI) was applied around the gel disc to slow down gel dehydration.  
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A dynamic strain sweep was performed at a frequency of 1 Hz at room temperature.  
The applied strain ranged from 1 μm to 50 μm.  The storage modulus (E’) and loss 
modulus (E”) versus amplification were obtained.  This information was used to 
ensure the frequency sweep tests were performed in the linear viscoelastic region where 
the measured mechanical properties are strain independent.  A frequency sweep at a 
cyclic stain of 10 μm and preload force of 0.01 N was then performed over a range of 1 
- 100 Hz, and graphs of the storage modulus (E’) and loss modulus (E”) versus 
frequency  were obtained.  These parameters are related by the following equations 
[45]: 
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                 (4) 
where E is the dynamic modulus, dtan  is loss tangent (damping ratio).  The storage 
modulus represents elasticity of hydrogel, which means the capability of hydrogel to 
store mechanical energy and resist deformation.  The loss modulus represents 
viscosity of hydrogel, a measurement of hydrogel’s ability to resist shear flow. 
3.7. Biochemical Assays 
3.7.1. Hydrolysis of Samples 
Samples were harvested at day 3, day 30 and day 70 of culture then transferred to 
screw-cap vials, weighed, flash-frozen in liquid nitrogen, and stored at -80ºC.   
Hydrogel samples were digested in 1 ml 0.1 N NaOH per 0.2 g hydrogel wet weight for 
72 h at 37˚C.  Digested hydrogel solutions were centrifuged (10,000 x g for 10 min), 
and a portion of each digest was taken for DNA and GAG quantification.  Remaining 
solution was digested at 90 - 100˚C for 90 min to solubilize collagen but not elastin 
fibers.  Hydrolyzed samples were centrifuged at 10,000 x g for 10 min to pellet 
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elastin.  The supernatant was kept for collagen quantification.  The elastin pellets 
were washed by diH2O at least four times and stored at -80˚C until use.  
3.7.2. DNA Analysis 
The DNA content in the gels was determined using a PicoGreen double-stranded DNA 
assay (Molecular Probes; Invitrogen, Carlsbad, CA) [30].  PEG hydrogels containing 
calf thymus DNA (Sigma, St. Louis, MO) were used as standards, which had 
experienced the same base hydrolysis conditions as the samples.  Duplicate 40 μL 
aliquots of standards and samples were used in this assay such that all samples had the 
same concentrations of PEG.  Samples were analyzed according to the manufacturer’s 
instructions, using a Multi-Detection Microplate Reader (BioTek, Winooski, VT) with 
excitation filter at 480 nm and emission filter at 520 nm.  A sample size of 6 was used. 
The cell number in each hydrogel was computed by using the conversion factor of 6.6 
pg DNA per pig cell [30].    
3.7.3. Sulfated GAGs Analysis 
Sulfated GAGs production was measured with the Blyscan assay kit (Biocolor, 
Newtownabbey, Northern Ireland) [46].  This assay is based on the complex formation 
of dimethylmethylene blue with sulfated GAGs, a complex with an absorbance 
maximum at 525 nm. PEG hydrogels containing chondroitin sulfate B sodium salt 
(C3788; Sigma, St. Louis, MO) and which had experienced the same base hydrolysis 
conditions as the samples, were used as standards.  Duplicate 80 μL aliquots of 
standards and samples were used such that all specimens had the same concentrations 
of PEG.  The samples were neutralized with 10 N HCl (Fisher Scientific, Fair Lawn, 
NJ) and then mixed with 120 μL Blyscan Dye reagent.  The resultant solution was 
measured immediately without delay using a Multi-Detection Microplate Reader at 525 
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nm.  A sample size of 3 was used.  The measured sulfated GAG content was 
expressed as micrograms of sulfated GAG per cell.  
3.7.4. Collagen Content Measured by Hydroxyproline Assay 
The hydroxyproline content, which is an indirect indicator of collagen, was 
determined by the dimethylbenzaldehyde (DMBA) assay.  Aliquots of base-digests 
were combined with an equivalent volume of concentrated HCl (37%) to generate a 6N 
HCl solution and hydrolyzed 18 h at 110 ˚C in tubes with silicone-sealed gaskets.  
Acid hydrolyzed samples were dried by centrivap (Labconco. Kansas City, MI) and 
reconstituted in 100 μl diH2O.  Samples were combined with 50 μL freshly prepared 
chloramine-T solution [88 mg chloramine-T in 0.625 ml isopropanol / 5 ml PH 6 buffer 
(2.24% Sodium Hydroxide, 3.2% Citric Acid Monohydrate, 8% Sodium Acetate 
Trihydate, 0.8% Acetic Acid Glacial, 20% Isopropanol; pH = 6.0)] and incubated for 
15 min at room temperature.  Samples were then mixed with 50 μL 
p-Dimethylbenzaldehyde reagent (1.25 g p-Dimethylbenzaldehyde in 5 ml Isopropanol, 
2.25 ml Perchloric acid) and incubated at 37˚C for 30 min.  The absorbance of samples 
at 550 nm was read with Multi-Detection Microplate Reader.  PEG hydrogels 
containing L-4-hydroxyproline (Fluka, Milwaukee, WI) and which had experienced 
the same hydrolysis conditions as the samples, were used as standards.  A sample 
size of 3 was used.  Total collagen content was estimated from measured grams of 
hydroxyproline by dividing by 0.13, a conversion factor for collagen type I that is 
highly consistent across mammalian species [47]. Total collagen levels were 
expressed relative to the total cell density in the hydrogels. 
3.7.5. Elastin Content Measured by Ninhydrin Assay 
Elastin content was determined using the ninhydrin assay [48].  Elastin pellets were 
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digested in 6 N HCl at 110 ˚C for 18 h in tubes with silicone-sealed gaskets.  Samples 
were then dried by centrivap and reconstituted in 220 μl 0.1 M sodium citrate buffer 
(pH = 5.0).  An equivalent volume of ninhydrin reagent (Sigma, St. Louis, MO) was 
added to the samples and samples were boiled for 15 min.  After cooling to room 
temperature, the absorbance of samples was read using a Multi-Detection Microplate 
Reader at 570 nm.  A sample size of 3 was used.  Hydrolyzed elastin (MP 
Biochemicals, Solon, Ohio) was used as the standard.  The measured elastin content 
was expressed as micrograms of elastin per cell.  
3.8. Histological Analysis and Immunohistochemistry 
Hydrogel constructs were fixed with 10% formalin for 30 min, embedded in Tissue-Tek 
embedding media (Sakura Finetek, Torrance, CA) and sectioned at a thickness of 35 μm 
using a cryostat (Histotronix, Omaha, NE).  Following the standard histological 
staining procedures, the cryosections were stained with toluidine blue solution 
(0.0714% toluidine blue (Fluka, Milwaukee, WI), 0.0714% pyronin Y (Fluka, 
Milwaukee, WI), and 0.143% borax (Fisher Scientific, Fair Lawn, NJ)) for 6 min to 
detect sulfated GAG.  The collagen fibers were detected by staining with Picrosirius 
red solution (50 mg Sirius red F3B in 50 mL Saturated aqueous solution of picric acid) 
for 1 h.  Stained sections were imaged using an Axiovert A200 microscope (Zeiss, 
Germany).   
 
Sections for immunohistochemical staining were treated with 10% non-immune goat 
serum for 30 min.  After treatment with goat serum, specimens were incubated at 
room temperature with primary antibody for elastin (mouse, Sigma, St. Louis, MO), 
collagen type I (rabbit, Rockland, Gibbertsville, PA), smooth muscle α-actin (mouse, 
 23 
NeoMarkers, Fremont, CA) and vimentin (mouse, MS-129, NeoMarkers, Fremont, 
CA), then followed by the treatment with peroxidase (Biocare Medical, Concord, CA) 
for 30 min.  The sections were treated with appropriate secondary antibody followed 
by streptavidin-biotin immunoenzymatic antigen detection kit (Zymed, South San 
Francisco, CA).  Samples were stained without primary antibody as a negative 
control.  Stained sections were imaged using an Axiovert A200 microscope (Zeiss, 
Germany).  To determine the cell phenotype, the ratio of vimentin-positive and 
SMα-actin-positive cells in the samples at day 70 were calculated by the number of 
vimentin-positive or SMα-actin-positive cells in an immunohistochemical staining 
section divided by the sum of the cells in the same section.   
3.9 Statistical Analysis 
All data were reported as means ± standard deviation.  The statistical analysis was 
performed by one-way ANOVA and Tukey’s post hoc test using SigmaStat 3.5 (Systat 
Software, Inc. San Jose, CA).  p < 0.05 was considered to be significantly different.  
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4. RESULTS 
The results from the experiments described in Materials and Methods are presented 
below. 
4.1. Determination of Mesh Size 
The network microstructures of hydrogels with different PEGDA macromer 
concentrations were characterized by swelling studies.  The polymer equilibrium 
water content ( q ), the number average molecular weight between crosslinks ( cM ), 
and mesh size (z ) were tabulated (Table 3) from these swelling ratios and the 
relationships detailed in PEG hydrogel mesh size and swelling.  As shown in Table 3, 
although the equilibrium water content decreased slightly with increasing PEGDA 
macromer concentration, there was no statistically significant difference in z  
observed for different PEGDA hydrogels.  This result is consistent with Cruise GM 
et al.’s results [40]. 
 
Table 3. Effect of PEGDA Concentration on the Network Structure of PEGDA 
Hydrogels 
 
% PEGDA q (%) cM  (g/mol) z  (Å) 
10% 92.10 ± 0.16 1220 ± 37 66.8 ± 1.4 
20% 89.76 ± 0.05 1360 ± 9 63.6 ± 0.3 
30% 88.54 ± 0.58 1407 ± 85 63.4 ± 3.0 
 
4.2. Mechanical Properties of PEGDA Hydrogels 
In order to determine the initial mechanical environment experienced by PVFF, the 
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modulus of cell-hydrogel constructions were measured.  Figure 5 (a) and (b) show 
the representative curves of storage modulus and loss modulus versus amplitude and 
frequency respectively.  In Figure 5 (a), storage modulus and loss modulus remain 
constant after 10 μm, which means the measured moduli are strain independent.  
Figure 5 (b) shows storage modulus and loss modulus increased slowly with 
frequency, similar with previous observations of vocal fold tissue [5].  Since the 
major length changes of vocal folds during phonation occur at about 10 Hz and below 
[49], the storage modulus and loss modulus data of cell-hydrogel constructs at 1 Hz 
oscillatory frequency and 10μm strain from dynamic strain sweep measurement were 
tabulated (Table 4).  Storage modulus of PEGDA hydrogels (p < 0.002) was 
increased with PEGDA macromer concentration in precursor solution.  Only loss 
modulus of 10% PEGDA and 20% PEGDA gels showed significant difference (p = 
0.018) and damping ratio (p = 0.813) of all the formulations were not significant 
different.  In order to understand the viscoelasticity during high frequency during 
phonation, the mechanical of cell-hydrogel constructs at 40 Hz oscillatory frequency 
were determined by frequency sweep measurement (Table 4) (p < 0.025).  It showed 
the similar trend as the data from strain sweep, with the storage modulus increasing 
with macromer concentration.  The results of the mechanical testing combined with 
that of the swelling studies indicate that these hydrogel formulations can be used to 
probe the effects of mechanical properties on ECM synthesis uncoupled from 
variations in network structure.  
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Figure 5. (a) Storage modulus ( 'E ) and loss modulus ( ''E ) of cell-hydrogel constructs 
(◆ Storage modulus, ■ Loss modulus) as a function of amplification for 30% 
PEGDA gels; (b) Storage modulus ( 'E ) and loss modulus ( ''E ) of cell-hydrogel 
constructs as a function of frequency for 30% PEGDA. 
Table 4. Mechanical Properties of PEGDA Hydrogels 
 Stain sweep a Frequency sweep b 
% PEGDA 'E c (kPa) ''E d (kPa) dtan e 'E c (kPa) ''E d (kPa) dtan e 
10% 23.62 ± 1.70 * 2.54 ±1.48 0.108 ± 0.063 28.19 ± 0.12 * 12.84 ± 0.67 0.456 ± 0.024 
20% 72.61 ± 4.76 * 12.25 ± 1.40 0.169 ± 0.022 87.54 ± 10.09 * 49.34 ± 13.89 0.564 ± 0.171 
30% 94.25 ± 2.81 * 8.05 ±3.52 0.085 ±0.037 109.18 ± 3.25 * 35.44 ± 5.97 0.325 ± 0.056 
 
a. Data was obtained at 10 μm at 1 Hz of strain sweeping measurement. (N = 3) 
b. Data was obtained at 10 μm at 40 Hz of frequency sweeping measurement. (N = 3) 
c. Storage modulus (elastic modulus) 
d. Loss modulus (viscous modulus) 
e. Damping ratio (the ratio of loss modulus to storage modulus) 
* p < 0.05 
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4.3. Cell Density 
Cell density in each hydrogel was assessed by determining hydrogel DNA levels.  
These measures were then used to calculate ECM production in each construct on a per 
cell basis.  The cell density decreased by approximately 50% in 20% gels (p < 0.001) 
and 30% gels (p < 0.001) from day 3 to day 30, while no significant change in cell 
density was observed in 10% gels (p = 0.904) (Figure 6).  However, there was no 
further cell density reduction in the 20% gels (p = 0.938) and 30% gels (p = 0.895) 
from day 30 to day 70. 
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Figure 6. Cell density/ml of PVFF encapsulated in 10%, 20% and 30% PEGDA 
hydrogels at day 3, day 30 and day 70. 
 
4.4. Matrix Synthesis in Hydrogels  
PEGDA constructs were harvested from culture at day 3, day 30 and day 70 for 
biochemical analysis.  The measured GAGs/cell, collagen/cell and elastin/cell are 
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shown in Figures 7 (a), (b) and (c), respectively, as a function of time in culture and 
gel composition.  Note that these data indicate that PVFF cells start to synthesize 
significant levels of new matrix within a short culture period (3 days).  By day 3, 
PVFF in 10% gels produced significantly less GAGs/cell and collagen/cell than those 
in 30% gels (p < 0.001, p = 0.026 respectively) while PVFF in all gels produced 
similar amount of elastin (p = 0.930).  By 30 days of static culture, however, the 
constructs generated from 20% PEGDA macromer solution promoted higher 
elastin/cell production than 10% and 30% PEGDA hydrogels (p < 0.001 and p = 0.004 
respectively).  Increased GAGs with increasing scaffold storage modulus from 10% 
to 30% PEGDA hydrogels was also noted both at 30 days and 70 days of culture (p < 
0.002).  Although collagen/cell levels in 20% and 30% PEGDA hydrogels were 
greater than those in 10% hydrogels after 30 days culture, no difference was observed 
between 20% and 30% gels.  Interestingly, maximum ECM contents was observed in 
the hydrogels of intermediate storage modulus (20% PEGDA hydrogels) and total 
amount of major ECM components was lowest in the hydrogels of lowest storage 
modulus (10% PEGDA hydrogels) after day 30 (p < 0.001) and day 70 (p < 0.001).   
 
However, the effect of culture time on cellular ECM production was small.  More 
specifically, no significant difference was found in GAGs/cell production in 10%, 
20% and 30% PEGDA hydrogels (p = 0.088, p = 0.373 and p = 0.058 respectively), in 
collagen/cell production in 30% PEGDA hydrogels (p = 0.062) and in elastin/cell 
production in 10% and 30% PEGDA hydrogels (p = 0.540 and p = 0.159 respectively) 
over the culture time.  Furthermore, the total amount of major ECM components in 
20% and 30% PEGDA hydrogels didn’t increase significantly from day 30 to day 70 
(p = 0.758 and p = 0.169 respectively).  
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 (b) 
Figure 7. Cellular ECM production for 10%, 20% and 30% gels at day 3, day 30 and 
day 70: (a) sulfated GAGs, (b) collagen, (c) elastin, (d) the sum of sulfated GAGs, 
collagen and elastin per cell.   
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(d) 
Figure 7. Continued. 
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4.5 Histological Analysis 
In addition to quantification of biochemical contents of PEGDA constructs, it is also 
important to learn the spatial distribution of ECM.  The representative GAGs staining 
image, Figure 8 (a), revealed that PVFF had deposited GAGs only surrounding 
individual cells and no diffusion was observed.  A similar pericellular distribution was 
observed in all 10%, 20% and 30% PEGDA gel constructs.  Figure 8 (b) and (c) 
demonstrate that collagen and elastin were retained in the pericellular region and the 
region between cells.     
 
 
 
(a) 
Figure 8. Representative images of major ECM protein distribution in PEGDA 
hydrogels after 70 days in vitro.  These sections were from the 10% PEGDA 
hydrogels. (a) Collagen staining, picrosirius red straining collagen red; (b) GAGs 
staining, toluidine blue staining GAGs purple; (c) Elastin immunostaining,  AEC 
chromogen yielding a deep red stain for elastin.  The scale bar represents 50 μm. 
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(b) 
 
(c) 
Figure 8. Continued. 
 
In addition to the total amount and distribution of collagen, the type of collagen 
produced is important.  In lamina propria, the most abundant type of collagen is type I.   
The immunohistological analysis for collagen type I provide in-depth understanding in 
collagen distribution and organization.  The representative images for collagen type I 
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immunohistological analysis in day 30, Figure 9 (a), (b) and (c), showed the 
organization of collagen was affected by the gel mechanical properties.  In the 30% 
PEGDA hydrogel, with highest storage modulus, a collagen network structure between 
cells and some thick bundles of collagen were observed.  Lowest staining density was 
found for collagen type I in 10% PEGDA hydrogel whereas no significant difference 
was observed between 20% and 30% PEGDA hydrogels staining, which is consistent 
with biochemical analysis.  
 
 
 
(a) 
Figure 9. Immunohistological analysis of collagen type I after 30 days in vitro.  AEC 
chromogen yields a deep red stain for collagen type I, (a) 10% PEGDA, (b) 20% 
PEGDA, (3) PEGDA.  The scale bar represents 50 μm. 
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(b) 
 
(c) 
Figure 9. Continued. 
 
Differentiation of PVFF in these gels is a major concern because the cells might change 
their phenotype into myofibroblasts in response to the mechanical microenvironment 
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around them.  Immunohistochemistry was performed on these cell-hydrogel 
constructs after day 70 to assess cell phenotype, and the results are shown in Table 5. 
The vimentin amount increased with hydrogels’ storage modulus (p < 0.001) and 10% 
PEGDA hydrogels showed fewest SMα-actin-positive cells.  Since SMα-actin is only 
expressed in the myofibroblasts and myofibroblast also showed enhanced vimentin 
expression relative to fibroblasts [18], there appear to be more myofibroblasts in 20% 
and 30% PEGDA hydrogels. 
 
Table 5. Vimentin and SMα-actin Ratio in PEGDA Hydrogels b 
Sample Vimentin ratio a SMα-actin ratio a 
10% PEGDA gels 0.371 ± 0.021 * 0.196 ± 0.000 * 
20% PEGDA gels 0.520 ± 0.018 * 0.257 ± 0.012 
30% PEGDA gels 0.591 ± 0.006 * 0.235 ± 0.003 
 
a.  The ratio of vimentin-positive and SMα-actin-positive cells in the samples at day 
70 were calculated by the number of vimentin-positive or SMα-actin-positive cells in 
an immunohistochemical staining section divided by the sum of the cells in the same 
section. 
b. N=2 
* p < 0.05 
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5. DISCUSSION 
Injectable hydrogels are highly desirable for vocal fold augmentation applications 
since they prevent further scarring induced by surgical procedures. PEG based 
hydrogels have been widely explored as encapsulation scaffolds suitable for tissue 
engineering due to their inherent biocompatibility and the fact that they are 
photopolymerizable materials, suitable for injectable implants without the need for 
invasive surgical intervention [30, 34 - 38].  In addition, PEGDA hydrogel is a cell 
nonadhesive substrate upon which cell-specific bioactivity can be written.  They 
have been used as a model substrate to study 3-D migration [34].  The results 
presented here demonstrate the suitability of PEG as a model scaffold for examining 
the effects of mechanical properties of cell-hydrogel constructs on vocal fold 
fibroblasts’ response.  We hypothesized that the intrinsic mechanical properties of 
the microenvironment might influence cell ECM production.  To carry out these 
experiments, we first needed to verify that mechanical properties and other scaffold 
features, like biochemistry and network structure can be tuned in an uncoupled 
manner, which implies that changing mechanical properties of PEGDA scaffolds does 
not simultaneously influence scaffold chemistry and network structure. 
 
First of all, we characterized the bulk mechanical properties of PEG hydrogels to 
show that varying the macromer concentration in precursor solution enables 
systematic control over their mechanical properties (the storage modulus ranging from 
23.62 ± 1.70 kPa to 94.25 ± 2.81 kPa), which agreed with previous studies on PEGDM 
hydrogels by Bryant et al.[33].  A higher storage modulus indicates a stiffer hydrogel.  
Furthermore, the swelling studies indicated there was no significant difference 
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between mesh size of hydrogel network for 10%, 20% and 30% PEGDA hydrogels.  
Thus, the gel mechanical properties were decoupled with mesh size successfully.  In 
addition, since we modified the total RGDS amount/gel volume according to the 
swelling data, we could assume the RGDS density was held constant across all 
conditions.  Any changes in cell behavior were then attributed to the change in 
PEGDA hydrogel mechanical properties.   
 
From day 3 to day 30, the PVFF density in 20% and 30% PEGDA gel constructs was 
reduced while there was no significant cell density reduction in 10% PEGDA gel 
constructs.  The decrease in cell density was observed in the PEGDA hydrogels since 
no adequate room was provided in non-degradable PEGDA hydrogels for cell to 
divide and migrate and the tightly cross-linked hydrogel (mesh size ~ 63 Å) hampered 
the extent of spreading of encapsulated cells.  These results agree with the previous 
report that higher PEGDA composition in the gels comprises the cell viability over 
culture time [40].  
 
Biochemical data indicated the stiffer PEGDA hydrogels allowed the encapsulated 
PVFF to synthesize more collagen but that increasing the stiffness beyond a certain 
point could not increase collagen production.  Thus, there appears to be an optimal 
stiffness at the present mesh size for PVFF to produce maximum elastin and collagen.  
To investigate the composition of ECM in different PEGDA hydrogels, we compared 
the ratio of elastin to collagen and GAG to collagen.  As shown in Figure 10, the 
ratio of elastin to collagen decreased with an increase in gel stiffness (p < 0.002) and 
the higher ratio of GAGs to collagen was observed in 30% PEGDA hydrogels (p < 
0.01).  It indicates PVFF embedded in 30% PEGDA hydrogel synthesize more 
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GAG-rich ECM than other two kinds of PEGDA hydrogel while those in 10% 
PEGDA hydrogel produce more elastin-rich ECM.  This result suggests the 
composition of ECM synthesis by cells can be altered by inherent mechanical 
properties of scaffold.  Thus, it is possible to define optimal gel mechanical 
properties to control ECM composition according to different requirements for tissue 
engineering application. 
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(a) 
Figure 10. ECM composition synthesized by PVFF encapsulated in 10%, 20% and 
30% PEGDA hydrogels after day 30 and day 70, (a) the ratio of elastin to collagen, (b) 
ratio of GAGs to collagen.  * representing the significant difference, p < 0.05. 
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Figure 10. Continued. 
 
The data from day 30 to day 70 indicated culture time influenced GAGs/cell and 
elastin/cell production little. However, a decrease of collagen/cell production in 10% 
PEGDA hydrogels was observed from day 30 to day 70.  The probable reason for 
this decrease may be explained by the well-known balance of ECM synthesis and 
degradation by matrix metalloproteinases (MMPs) [2].  ECM regulation is a 
precisely controlled process dependent not only on the amount of produced proteins, 
but also on activation or inhibition of MMPs by the tissue inhibitors of MMPs 
(TIMPs).  This hypothesis is waiting to be tested by studying gene expression of 
collagen, MMP1 and TIMP4 using reverse transcriptase polymerase chain reaction.   
 
The histological analysis showed GAGs, collagen and elastin to be present only 
around the cells in all three systems.  The inhomogeneous GAGs, collagen and 
elastin distribution is due to tightly cross-linked hydrogel network.  It is estimated 
the size of a small sized GAGs aggregate is approximately 90 Å in width and the size 
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of collagen type I fiber is 20 nm in average and elastin microfibrils can range from 
110 – 130 nm in diameter [33, 50, 51].  The mesh size of PEGDA hydrogel 
investigated is ~ 63 Å, which is lower than the reported GAGs, collagen and elastin 
sizes.  Therefore, it is expected that the newly synthesized collagen, elastin and 
GAGs are restricted to the pericellular regions.  The immunohistological analysis for 
collagen suggested a dependence of collagen organization on gel stiffness.  It was 
found collagen assembled into thick bundles in 30% PEGDA hydrogel, which is with 
highest storage modulus.  This result is similar with the VFF’s behavior in scarred 
tissue, in which fibroblasts undergo a phenotype change to myofibroblasts [2].  To 
test the hypothesis that the mechanical microenvironment around the cells might 
cause the phenotype change of vocal fold fibroblasts, the immunohistological analysis 
for vimentin and SMα-actin was performed.  The primary result for cell phenotypes 
in the PEGDA hydrogels showed more myofibroblasts in 20% and 30% PEGDA 
hydrogels with higher stiffness.  This change allows fibroblast to be more effective at 
ECM synthesis not only in maintaining the tissue but also repairing it.  Clearly, to 
verify the hypothesis further, additional quantitative experiments are necessary to 
determine PVFF phenotype in PEGDA hydrogels.  
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6. CONCLUSION AND FUTURE RESEARCH 
The aim of this study was to determine the effect of mechanical properties of PEGDA 
hydrogels on PVFF’s behavior uncoupled from microstructural and biochemical 
property alterations.  We demonstrated the gel mechanical properties were decoupled 
from mesh size of polymer network by varying the PEGDA macromer concentration.  
The biochemical analysis data suggested that increasing GAGs/cell and collagen/cell 
production was observed from 10% PEGDA hydrogels with lowest storage modulus to 
20% PEGDA hydrogels.  However, collagen/cell production did not change 
significantly with the further increase in storage modulus seen from the 20% to the 30% 
gels.  Elastin/cell production is highest in 20% PEGDA hydrogel with intermediate 
storage modulus.  In addition, the organization of collagen molecules in hydrogels and 
cell phenotype appeared to be influenced by the inherent mechanical properties of 
PEGDA hydrogels.  Thus, the mechanical microenvironment around cell can control 
the composition of newly synthesized ECM and cell phenotypes. This PEGDA 
platform for investigating cell responses to specific scaffold property changes should 
allow optimal scaffold property design based on the requirements for clinical outcome 
of lamina propria engineering. 
 
The PEGDA hydrogel model validated herein can be used to systematically study the 
complex interactions between scaffold features and cell response.  The following 
scaffold features on VFF behavior can be investigated by this model: 
1) Mesh size of the hydrogel network.  Our previous study has shown 20% MW 
10,000 PEGDA gel has the similar mechanical properties with 30% MW 20,000 
PEGDA gel although they have different mesh size.   
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2) Biochemical properties.  ECM components, like collagen, fibronectin, hyaluronic 
acid provide different biochemical stimuli to VFF.  Many different types of ligands 
and molecules, derived from ECM components, can be covalently immobilized into 
a cell nonadhesive PEGDA hydrogel during photopolymerization to investigate 
single biochemical properties impacts on cell’s response [34, 38].  
3) Degradation rate.  Biodegradable or bioerodible PEG hydrogels have been 
developed when hydrolytically degradable polymer segments or proteolytically 
degradable peptides were co-polymerized with PEG as a BAB block copolymers 
and then terminated with acrylate groups.  By appropriately selecting the 
degradable segments, different hydrogel degradation rates can be achieved [33, 38].  
 
These results from above proposed research on the effects of isolated scaffold features 
on VFF response will be important for rational scaffold design or implant material 
screening and will eventually benefit vocal fold restoration. 
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APPENDIX 
A.1. Water content 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 92.097 0.16 0.113
Sample-20% 2 0 89.761 0.0531 0.0376
Sample-30% 2 0 88.543 0.577 0.408  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 13.05 6.525 54.097 0.004
Residual 3 0.362 0.121
Total 5 13.412  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
10% vs. 30% 3.554 3 14.474 0.004 Yes
10% vs. 20% 2.336 3 9.512 0.014 Yes
20% vs. 30% 1.219 3 4.962 0.078 No  
A.2. Molecular weight between crosslinks 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 1220 37 26.163
Sample-20% 2 0 1360 9 6.364
Sample-30% 2 0 1407 85 60.104  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 37852 18926 6.545 0.081
Residual 3 8675 2891.667
Total 5 46527  
A.3. Mesh size 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 66.805 1.427 1.009
Sample-20% 2 0 63.569 0.324 0.229
Sample-30% 2 0 63.403 2.981 2.108  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 14.715 7.357 2.002 0.28
Residual 3 11.024 3.675
Total 5 25.739  
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A.4. Mechanical properties 
A.4.1. Storage modulus-strain sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 23.615 1.704 1.205
Sample-20% 3 0 72.613 4.76 2.748
Sample-30% 3 0 94.25 2.806 1.62  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 6069.234 3034.617 237.231 <0.001
Residual 5 63.959 12.792
Total 7 6133.193  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 70.635 3 30.596 <0.001 Yes
30% vs. 20% 21.637 3 10.478 0.002 Yes
20% vs. 10% 48.998 3 21.224 <0.001 Yes  
A.4.2. Loss modulus-strain sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 2.543 1.478 1.045
Sample-20% 3 0 12.256 1.403 0.81
Sample-30% 3 0 8.051 3.522 2.034  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 113.404 56.702 9.164 0.021
Residual 5 30.936 6.187
Total 7 144.34  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 9.713 3 6.049 0.018 Yes
20% vs. 30% 4.206 3 2.929 0.191 No
30% vs. 10% 5.507 3 3.43 0.126 No  
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A.4.3. dtan -strain sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 0.108 0.0631 0.0446
Sample-20% 3 0 0.169 0.0223 0.0129
Sample-30% 3 0 0.0854 0.0375 0.0216  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 0.011 0.0055 3.534 0.111
Residual 5 0.00778 0.00156
Total 7 0.0188  
A.4.4. Storage modulus-frequency sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 28.193 0.12 0.0845
Sample-20% 3 0 87.541 10.088 5.824
Sample-30% 3 0 109.178 3.246 1.874  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 8087.22 4043.61 90.006 <0.001
Residual 5 224.629 44.926
Total 7 8311.849  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 80.985 3 18.718 <0.001 Yes
30% vs. 20% 21.637 3 5.591 0.025 Yes
20% vs. 10% 59.348 3 13.717 <0.001 Yes  
A.4.5. Loss modulus-frequency sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 12.845 0.675 0.477
Sample-20% 3 0 49.345 13.89 8.019
Sample-30% 3 0 35.443 5.974 3.449  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 1599.612 799.806 8.738 0.023
Residual 5 457.682 91.536
Total 7 2057.294  
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All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 36.5 3 5.91 0.02 Yes
20% vs. 30% 13.902 3 2.517 0.268 No
30% vs. 10% 22.598 3 3.659 0.105 No  
A.4.6. dtan -frequency sweep 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 0.456 0.024 0.017
Sample-20% 3 0 0.564 0.171 0.099
Sample-30% 3 0 0.325 0.0556 0.0321  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 0.0859 0.043 3.277 0.123
Residual 5 0.0655 0.0131
Total 7 0.151  
A.5. Cell density 
A.5.1. Cell density in day 3 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 393865.749 42482.11 24527.06
Sample-20% 3 0 306287.63 30872.04 17823.98
Sample-30% 3 0 306305.73 46676.68 26948.79
 
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 15336684331 7668342165 4.66 0.06
Residual 6 9873049638 1645508273
Total 8 25209733969
 
A.5.2. Cell density in day 30 
Group Name  N  Missing Mean Std Dev SEM 
Sample-10% 6 0 374210.9 78019 31851.1 
Sample-20% 6 0 134178.8 25161.8 10272.3 
Sample-30% 6 0 185241 41824.5 17074.8 
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Source of Variation  DF   SS   MS    F    P  
Between Groups 2 1.92E+11 9.59E+10 33.981 <0.001 
Residual 15 4.23E+10 2.82E+09     
Total 17 2.34E+11       
 
All Pairwise Multiple Comparison Procedures (Tukey Test):  
Comparisons for factor:      
Comparison Diff of Means p q P P<0.050 
10% vs. 20% 240032 3 11.066 <0.001 Yes 
10% vs. 30% 188970 3 8.712 <0.001 Yes 
30% vs. 20% 51062.1 3 2.354 0.251 No 
 
A.5.3. Cell density in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 381531.116 37912.9 18956.45
Sample-20% 4 0 142837.287 39479.63 19739.82
Sample-30% 4 0 197641.454 41271.71 20635.86
 
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 1.25058E+11 62529099008 39.917 <0.001
Residual 9 14098152377 1566461375
Total 11 1.39156E+11
 
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
10% vs. 20% 238693.8 3 12.062 <0.001 Yes
10% vs. 30% 183889.7 3 9.292 <0.001 Yes
30% vs. 20% 54804.17 3 2.769 0.178 No
 
A.5.4. Cell density in 10% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 393865.749 42482.11 24527.06
Day 30 6 0 374210.917 78019.03 31851.14
Day 70 4 0 381531.116 37912.9 18956.45
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Source of Variation  DF  SS  MS   F   P 
Between Groups 2 774260753.8 387130376.9 0.101 0.905
Residual 10 38356467137 3835646714
Total 12 39130727891
 
A.5.5. Cell density in 20% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 306287.63 30872.04 17823.98
Day 30 6 0 134178.831 25161.84 10272.28
Day 70 4 0 142837.287 39479.63 19739.82  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 65813640382 32906820191 33.759 <0.001
Residual 10 9747680798 974768079.8
Total 12 75561321181  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day3 vs. Day30 172108.8 3 11.025 <0.001 Yes
Day3 vs. Day70 163450.3 3 9.694 <0.001 Yes
Day70 vs. Day30 8658.455 3 0.608 0.904 No  
A.5.6. Cell density in 30% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 306305.73 46676.68 26948.79
Day 30 6 0 185240.959 41824.53 17074.79
Day 70 4 0 197641.454 41271.71 20635.86  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 31477373045 15738686522 8.641 0.007
Residual 10 18213945869 1821394587
Total 12 49691318913  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day3 vs. Day30 121064.8 3 5.673 0.006 Yes
Day3 vs. Day70 108664.3 3 4.715 0.019 Yes
Day70 vs. Day30 12400.5 3 0.637 0.896 No  
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A.6. GAGs 
A.6.1. GAGs in day 3 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 1.43E-06 1.24E-06 0.000000719
Sample-20% 3 0 1.27E-05 1.99E-06 0.00000115
Sample-30% 3 0 1.64E-05 2.58E-06 0.00000149  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 3.64E-10 1.82E-10 44.874 <0.001
Residual 6 2.44E-11 4.06E-12
Total 8 3.89E-10  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.000015 3 12.86 <0.001 Yes
30% vs. 20% 3.7E-06 3 3.178 0.141 No
20% vs. 10% 1.13E-05 3 9.683 0.001 Yes  
A.6.2. GAGs in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 3.25E-06 1.47E-06 8.46E-07
Sample-20% 3 0 1.68E-05 5.02E-06 2.9E-06
Sample-30% 3 0 4.08E-05 1.13E-05 6.53E-06  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 2.16E-09 1.08E-09 20.908 0.002
Residual 6 3.1E-10 5.18E-11
Total 8 2.47E-09  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 3.75E-05 3 9.032 0.002 Yes
30% vs. 20% 2.39E-05 3 5.758 0.016 Yes
20% vs. 10% 1.36E-05 3 3.273 0.129 No  
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A.6.3. GAGs in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 1.29E-06 2.5E-07 1.25E-07
Sample-20% 4 0 2.04E-05 9.26E-06 4.63E-06
Sample-30% 4 0 4.06E-05 1.54E-05 7.7E-06  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 3.08E-09 1.54E-09 14.312 0.002
Residual 9 9.7E-10 1.08E-10
Total 11 4.05E-09  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 3.93E-05 3 7.565 0.001 Yes
30% vs. 20% 2.01E-05 3 3.879 0.054 No
20% vs. 10% 1.91E-05 3 3.687 0.067 No  
A.6.4. GAGs in 10% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.00000143 1.24E-06 7.19E-07
Day 30 3 0 0.00000325 1.47E-06 8.46E-07
Day 70 4 0 0.00000129 2.5E-07 1.25E-07  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 7.58E-12 3.79E-12 3.5 0.088
Residual 7 7.58E-12 1.08E-12
Total 9 1.52E-11  
A.6.5. GAGs in 20% PEGDA  
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.0000127 1.99E-06 1.15E-06
Day 30 3 0 0.0000168 5.02E-06 2.9E-06
Day 70 4 0 0.0000204 9.26E-06 4.63E-06  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.03E-10 5.13E-11 1.139 0.373
Residual 7 3.16E-10 4.51E-11
Total 9 4.18E-10  
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A.6.6. GAGs in 30% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.0000164 2.58E-06 1.49E-06
Day 30 3 0 0.0000408 1.13E-05 6.53E-06
Day 70 4 0 0.0000406 1.54E-05 7.7E-06  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.24E-09 6.18E-10 4.406 0.058
Residual 7 9.82E-10 1.4E-10
Total 9 2.22E-09  
A.7. Collagen 
A.7.1. Collagen in day 3 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.00016 0.000011 6.35E-06
Sample-20% 3 0 0.000178 1.22E-05 7.05E-06
Sample-30% 3 0 0.000236 4.13E-05 2.39E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 9.36E-09 4.68E-09 7.106 0.026
Residual 6 3.95E-09 6.59E-10
Total 8 1.33E-08  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 7.58E-05 3 5.113 0.026 Yes
30% vs. 20% 5.73E-05 3 3.866 0.076 No
20% vs. 10% 1.85E-05 3 1.247 0.671 No  
A.7.2. Collagen in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000115 1.57E-05 9.07E-06
Sample-20% 3 0 0.000376 4.38E-05 0.0000253
Sample-30% 3 0 0.000377 5.31E-05 0.0000306  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.36E-07 6.8E-08 40.943 <0.001
Residual 6 9.96E-09 1.66E-09
Total 8 1.46E-07  
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All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.000261 3 11.102 <0.001 Yes
30% vs. 20% 9.24E-07 3 0.0393 1 No
20% vs. 10% 0.00026 3 11.063 <0.001 Yes  
A.7.3. Collagen in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 7.03E-05 2.52E-05 0.0000126
Sample-20% 4 0 0.000273 7.54E-05 0.0000377
Sample-30% 4 0 0.000348 7.95E-05 0.0000397  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.65E-07 8.27E-08 19.633 <0.001
Residual 9 3.79E-08 4.21E-09
Total 11 2.03E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.000278 3 8.563 <0.001 Yes
30% vs. 20% 7.48E-05 3 2.306 0.283 No
20% vs. 10% 0.000203 3 6.257 0.004 Yes  
A.7.4. Collagen in 10% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.00016 0.000011 6.35E-06
Day 30 3 0 0.000115 1.57E-05 9.07E-06
Day 70 4 0 7.03E-05 2.52E-05 1.26E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.39E-08 6.94E-09 18.452 0.002
Residual 7 2.63E-09 3.76E-10
Total 9 1.65E-08  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day3 vs. Day70 8.97E-05 3 8.563 0.001 Yes
Day3 vs. Day30 4.46E-05 3 3.984 0.06 No
Day30 vs. Day70 4.51E-05 3 4.303 0.044 Yes  
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A.7.5. Collagen in 20% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000178 1.22E-05 7.05E-06
Day 30 3 0 0.000376 4.38E-05 2.53E-05
Day 70 4 0 0.000273 7.54E-05 3.77E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 5.84E-08 2.92E-08 9.642 0.01
Residual 7 2.12E-08 3.03E-09
Total 9 7.95E-08  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day30 vs. Day3 0.000197 3 6.208 0.008 Yes
Day30 vs. Day70 0.000102 3 3.446 0.101 No
Day70 vs. Day3 9.48E-05 3 3.192 0.129 No  
A.7.6. Collagen in 30% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000236 4.13E-05 2.39E-05
Day 30 3 0 0.000377 5.31E-05 3.06E-05
Day 70 4 0 0.000348 7.95E-05 3.97E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 0.000000034 1.7E-08 4.247 0.062
Residual 7 0.000000028 4E-09
Total 9 0.000000062  
A.8. Elastin 
A.8.1. Elastin in day 3 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000149 2.58E-05 1.49E-05
Sample-20% 3 0 0.000155 0.000063 3.64E-05
Sample-30% 3 0 0.000163 4.21E-05 2.43E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 3.13E-10 1.57E-10 0.0733 0.93
Residual 6 1.28E-08 2.14E-09
Total 8 1.31E-08  
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A.8.2. Elastin in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000169 0.000029 0.0000168
Sample-20% 3 0 0.000415 5.67E-05 0.0000327
Sample-30% 3 0 0.000227 0.000033 0.0000191  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 9.91E-08 4.96E-08 28.919 <0.001
Residual 6 1.03E-08 1.71E-09
Total 8 1.09E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 0.000246 3 10.286 0.001 Yes
20% vs. 30% 0.000188 3 7.865 0.004 Yes
30% vs. 10% 5.79E-05 3 2.42 0.276 No  
A.8.3. Elastin in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 0.000167 1.75E-05 8.76E-06
Sample-20% 4 0 0.000535 0.000143 0.0000715
Sample-30% 4 0 0.000216 0.000039 0.0000195  
Source of Variation  DF  SS  MS   F   P 
Between Groups 2 3.19E-07 1.6E-07 21.497 <0.001
Residual 9 6.69E-08 7.43E-09
Total 11 3.86E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 0.000368 3 8.537 <0.001 Yes
20% vs. 30% 0.000319 3 7.403 0.002 Yes
30% vs. 10% 4.89E-05 3 1.134 0.711 No  
A.8.4. Elastin in 10% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000149 2.58E-05 1.49E-05
Day 30 3 0 0.000169 0.000029 1.68E-05
Day 70 4 0 0.000167 1.75E-05 8.76E-06  
 60 
Source of Variation DF  SS  MS   F   P 
Between Groups 2 7.58E-10 3.79E-10 0.674 0.54
Residual 7 3.94E-09 5.63E-10
Total 9 4.7E-09  
A.8.5. Elastin in 20% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000155 0.000063 3.64E-05
Day 30 3 0 0.000415 5.67E-05 3.27E-05
Day 70 4 0 0.000535 0.000143 7.15E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 2.52E-07 1.26E-07 11.658 0.006
Residual 7 7.58E-08 1.08E-08
Total 9 3.28E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day70 vs. Day3 0.000381 3 6.777 0.005 Yes
Day70 vs. Day30 0.00012 3 2.145 0.34 No
Day30 vs. Day3 0.00026 3 4.333 0.043 Yes  
A.8.6. Elastin in 30% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000163 4.21E-05 2.43E-05
Day 30 3 0 0.000227 0.000033 1.91E-05
Day 70 4 0 0.000216 0.000039 1.95E-05  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 7.1E-09 3.55E-09 2.418 0.159
Residual 7 1.03E-08 1.47E-09
Total 9 1.74E-08  
A.9. Total ECM protein 
A.9.1. Sum of ECM protein in day 3 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000311 9.37E-06 5.41E-06
Sample-20% 3 0 0.000346 2.14E-05 0.0000124
Sample-30% 3 0 0.000416 1.97E-05 0.0000114  
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Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.71E-08 8.57E-09 27.572 <0.001
Residual 6 1.87E-09 3.11E-10
Total 8 1.9E-08  
A.9.2. Sum of ECM proteins in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000288 0.000011 6.36E-06
Sample-20% 3 0 0.000807 2.39E-05 0.0000138
Sample-30% 3 0 0.000644 2.12E-05 0.0000122  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 4.24E-07 2.12E-07 556.715 <0.001
Residual 6 2.28E-09 3.81E-10
Total 8 4.26E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 0.00052 3 46.137 <0.001 Yes
20% vs. 30% 0.000163 3 14.484 <0.001 Yes
30% vs. 10% 0.000357 3 31.653 <0.001 Yes  
A.9.3. Sum of ECM proteins in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.000239 1.02E-05 0.0000059
Sample-20% 3 0 0.000829 0.000054 0.0000312
Sample-30% 3 0 0.000605 2.99E-05 0.0000173  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 5.32E-07 2.66E-07 203.914 <0.001
Residual 6 7.83E-09 1.31E-09
Total 8 5.4E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 0.00059 3 28.289 <0.001 Yes
20% vs. 30% 0.000224 3 10.744 <0.001 Yes
30% vs. 10% 0.000366 3 17.544 <0.001 Yes  
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A.9.4. Sum of ECM proteins in 10% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000311 9.37E-06 0.00000541
Day 30 3 0 0.000288 0.000011 0.00000636
Day 70 4 0 0.000239 1.02E-05 0.00000511  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 9.46E-09 4.73E-09 45.264 <0.001
Residual 7 7.31E-10 1.04E-10
Total 9 1.02E-08  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day3 vs. Day70 7.16E-05 3 12.965 <0.001 Yes
Day3 vs. Day30 2.29E-05 3 3.889 0.065 No
Day30 vs. Day70 4.86E-05 3 8.808 0.001 Yes  
A.9.5. Sum of ECM proteins in 20% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000346 2.14E-05 1.24E-05
Day 30 3 0 0.000807 2.39E-05 1.38E-05
Day 70 4 0 0.000829 0.000054 0.000027  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 4.73E-07 2.36E-07 153.069 <0.001
Residual 7 1.08E-08 1.54E-09
Total 9 4.83E-07  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day70 vs. Day3 0.000483 3 22.776 <0.001 Yes
Day70 vs. Day30 2.17E-05 3 1.023 0.758 No
Day30 vs. Day3 0.000462 3 20.348 <0.001 Yes  
A.9.6. Sum of ECM proteins in 30% PEGDA 
Group Name N Missing Mean Std Dev SEM
Day 3 3 0 0.000416 1.97E-05 1.14E-05
Day 30 3 0 0.000644 2.12E-05 1.22E-05
Day 70 4 0 0.000605 2.99E-05 0.000015  
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Source of Variation DF  SS  MS   F   P 
Between Groups 2 9.19E-08 4.59E-08 73.754 <0.001
Residual 7 4.36E-09 6.23E-10
Total 9 9.63E-08  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
Day30 vs. Day3 0.000229 3 15.863 <0.001 Yes
Day30 vs. Day70 3.92E-05 3 2.912 0.169 No
Day70 vs. Day3 0.000189 3 14.046 <0.001 Yes  
A.10. The ratio of elastin to collagen 
A.10.1. Elastin/Collagen in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 1.462 0.0918 0.053
Sample-20% 3 0 1.103 0.055 0.0317
Sample-30% 3 0 0.604 0.0571 0.033  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 1.115 0.557 113.675 <0.001
Residual 6 0.0294 0.0049
Total 8 1.144  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
10% vs. 30% 0.858 3 21.229 <0.001 Yes
10% vs. 20% 0.359 3 8.877 0.002 Yes
20% vs. 30% 0.499 3 12.352 <0.001 Yes  
A.10.2. Elastin/Collagen in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 2.563 0.678 0.339
Sample-20% 4 0 2.047 0.586 0.293
Sample-30% 4 0 0.637 0.131 0.0655  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 7.945 3.972 14.55 0.002
Residual 9 2.457 0.273
Total 11 10.402  
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All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
10% vs. 30% 1.925 3 7.369 0.002 Yes
10% vs. 20% 0.516 3 1.975 0.383 No
20% vs. 30% 1.409 3 5.394 0.01 Yes  
A.11. The ratio of GAGs to collagen 
A.11.1. GAGs/Collagen in day 30 
Group Name N Missing Mean Std Dev SEM
Sample-10% 3 0 0.0281 0.0133 0.00766
Sample-20% 3 0 0.0448 0.0143 0.00828
Sample-30% 3 0 0.108 0.0337 0.0194  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 0.0107 0.00536 10.597 0.011
Residual 6 0.00303 0.000506
Total 8 0.0137  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.0801 3 6.17 0.011 Yes
30% vs. 20% 0.0634 3 4.884 0.032 Yes
20% vs. 10% 0.0167 3 1.286 0.655 No  
A.11.2. GAGs/Collagen in day 70 
Group Name N Missing Mean Std Dev SEM
Sample-10% 4 0 0.0183 0.00747 0.00374
Sample-20% 4 0 0.0747 0.0397 0.0198
Sample-30% 4 0 0.117 0.0516 0.0258  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 0.0194 0.00971 6.778 0.016
Residual 9 0.0129 0.00143
Total 11 0.0323  
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All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.0982 3 5.188 0.013 Yes
30% vs. 20% 0.0418 3 2.207 0.31 No
20% vs. 10% 0.0564 3 2.98 0.143 No  
A.12. The ratio of vimentin-positive cells (Day 70) 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 0.371 0.0215 0.0152
Sample-20% 2 0 0.52 0.0176 0.0124
Sample-30% 2 0 0.591 0.00644 0.00455  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 0.0502 0.0251 92.707 0.002
Residual 3 0.000812 0.000271
Total 5 0.051  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
30% vs. 10% 0.219 3 18.862 0.002 Yes
30% vs. 20% 0.0706 3 6.071 0.047 Yes
20% vs. 10% 0.149 3 12.791 0.006 Yes  
A.13. The ratio of SMα-actin-positive cells (Day 70) 
Group Name N Missing Mean Std Dev SEM
Sample-10% 2 0 0.196 0.000027 1.91E-05
Sample-20% 2 0 0.257 0.0118 0.00832
Sample-30% 2 0 0.235 0.00325 0.0023  
Source of Variation DF  SS  MS   F   P 
Between Groups 2 0.00385 0.00193 38.776 0.007
Residual 3 0.000149 4.97E-05
Total 5 0.004  
All Pairwise Multiple Comparison Procedures (Tukey Test):
Comparisons for factor: 
Comparison Diff of Meansp q P P<0.050
20% vs. 10% 0.0613 3 12.309 0.007 Yes
20% vs. 30% 0.0225 3 4.514 0.098 No
30% vs. 10% 0.0388 3 7.795 0.024 Yes  
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